These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7874885)

  • 21. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628).
    Sewell DL; Barry AL; Allen SD; Fuchs PC; Jorgensen JH; Tenover F
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):175-9. PubMed ID: 7648838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria.
    Fuchs PC; Barry AL; Pfaller MA
    J Antimicrob Chemother; 1994 Jun; 33(6):1147-54. PubMed ID: 7928808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
    Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM; Singh KV; Murray BE
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):195-201. PubMed ID: 10904193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
    Tali-Maamar H; Tebbal S; Rahal K
    Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
    Murphy SP; Cormican MG; Jones RN
    Ir J Med Sci; 1995; 164(4):271-3. PubMed ID: 8522427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae.
    Knapp JS; Neal SW; Parekh MC; Rice RJ
    Antimicrob Agents Chemother; 1995 Apr; 39(4):987-9. PubMed ID: 7786010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calibration of disk diffusion antibiotic susceptibility testing: species-related trovafloxacin interpretive zone breakpoints and selection of disk potency.
    Kronvall G; Rylander M; Walder M; Lind-Brandberg L; Larsson P; Törnqvist E; Monsen T
    Scand J Infect Dis; 1999; 31(6):573-8. PubMed ID: 10680988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality control limits for dilution and disk diffusion susceptibility tests of trovafloxacin against eight quality control strains.
    Fuchs PC; Barry AL; Brown SD
    J Clin Microbiol; 1998 Feb; 36(2):585-6. PubMed ID: 9466783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of in vitro antimicrobial activity of cefazolin alone and in combination with cefmetazole or flomoxef using agar dilution method and disk diffusion method].
    Matsuo K; Uete T
    Jpn J Antibiot; 1992 Oct; 45(10):1253-66. PubMed ID: 1479676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
    Jones RN; Deshpande LM; Erwin ME; Barrett MS; Beach ML
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():67-70. PubMed ID: 10824035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
    Pechère JC; Gootz TD
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.
    Cormican MG; Erwin MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):169-72. PubMed ID: 8724404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):55-64. PubMed ID: 9791759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
    Jones RN; Barrett MS; Biedenbach DJ
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The chemistry and biological profile of trovafloxacin.
    Brighty KE; Gootz TD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():1-14. PubMed ID: 9222064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.